Loading...
•
Dec 31, 2024
Arvinas Q4 2024 Earnings Report
Arvinas reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.
Key Takeaways
Arvinas reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline, including the upcoming topline data from the VERITAC-2 Phase 3 trial and the initiation of a Phase 1 trial with ARV-102 in patients with Parkinson's disease. The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2027.
Topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25.
Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity.
Planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer’s novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025.
Initiated a Phase 1 trial with ARV-102 in patients with Parkinson’s disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer’s Disease/Parkinson’s Disease congress.
Revenue by Segment
Forward Guidance
Arvinas anticipates several milestones including topline data from VERITAC-2, initiation of Phase 3 combination trials, and data presentations for ARV-393 and ARV-102. The company believes its current cash is sufficient to fund operations into 2027.
Positive Outlook
- Announce topline data for the VERITAC-2 Phase 3 monotherapy clinical trial evaluating vepdegestrant in patients with ER+/HER2- metastatic breast cancer (mBC) in a topline press release 1Q25 and present full results of the trial at a medical conference in 2025.
- Initiate two new Phase 3 combination trials in patients with ER+/HER2- mBC (pending emerging data and regulatory feedback) in 2025: First-line Phase 3 combination trial with Pfizer’s novel investigational CDK4 inhibitor, atirmociclib. Second-line Phase 3 combination trial with a CDK4/6 inhibitor.
- Continue to collect safety and efficacy data from ongoing TACTIVE-U sub-studies evaluating combination of vepdegestrant with abemaciclib, ribociclib, or samuraciclib (ClinicalTrials.gov Identifiers: NCT05548127, NCT05573555, and NCT06125522) and submit key data for presentation at medical conference.
- Continue enrollment in the Phase 2 TACTIVE-K clinical trial (atirmociclib + vepdegestrant) and submit initial Phase 1b data for presentation at a medical conference.
- Present preclinical data of ARV-393 in combination with standard of care biologic agents and small molecule inhibitors in high grade and aggressive diffuse large B-cell lymphoma in vivo models at the American Association for Cancer Research Annual Meeting (April 25-30, 2025).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...